Bsant Safwat Kassem

Dr. Bsant Safwat Kassem


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
MTMarwa S. Taha
Marwa S. Taha
BGBasant Mostafa Gabr
Basant Mostafa Gabr
WEWafaa Abd Elaziz
Wafaa Abd Elaziz
AEAhmed Mostafa Elgohary
Ahmed Mostafa Elgohary
BKBsant Safwat Kassem
Bsant Safwat Kassem
MGMona Abdelaziz Gadallah
Mona Abdelaziz Gadallah
It is crucial to identify Enterobacterales that produce carbapenemase to treat and manage hospital infections. The suggested techniques for their identification need a lengthy wait, technical knowledge, and training. Lateral flow immunoassays (LFIAs) provide a solution to these requirements. Thus, this study compared LFIA with phenotypic and genotypic tests for carbapenemase-producing bacteria. Fifty clinical isolates of carbapenem-resistant superbugs were examined. KPC, VIM, NDM, IMP, and OXA-48-like enzymes were evaluated and compared with phenotypic tests and LFIA. Regarding the phenotypic characteristics, the mCIM was positive in 37/50 (74%), and the eCIM was positive in 21/50 (42%). Regarding using LFIA, 41 out of the total isolates (82%) gave a positive red line with one or more of the tested genes. The most frequently detected gene was blaNDM (27/50 (54%)), and the least detected one was blaIMP (14/50 (28%)), which was in accordance with the PCR results. While investigating the accuracy of LFIA vs. PCR, it was found that LFIA had 100% sensitivity in the detection of the blaNDM and blaOXA genes, with 85.2% and 91.4% specificity, respectively, while for the blaIMP, blaKPC, and blaVIM genes, the values were 91.7% and 92.1%, 94.1% and 90.9%, and 95.5% and 89.3%, respectively. The overall accuracy of LFIA ranged from 92 to 94%. Our comparison with molecular assays revealed remarkable agreement, so we propose that this test might be utilized as a supplementary tool.

3 April 2026 in Toxicologie Analytique et Clinique
Verified
Journal Article
Closed access
NHNadia E. Helal
Nadia E. Helal
ASAsmaa Fady Sharif
Asmaa Fady Sharif
TMTarek Abdel Hay Mostafa
Tarek Abdel Hay Mostafa
BKBsant Safwat Kassem
Bsant Safwat Kassem
SESamah M. Elbastawesy
Samah M. Elbastawesy

15 June 2026 in Pathogens
Verified
Journal Article
Open access
PDF file
BGBasant Mostafa Gabr
Basant Mostafa Gabr
MGMona Abdelaziz Gadallah
Mona Abdelaziz Gadallah
WEWafaa Abd Elaziz
Wafaa Abd Elaziz
SMSama Fathy Mohamed Metwally
Sama Fathy Mohamed Metwally
RMRaghda Gabr Mashaal
Raghda Gabr Mashaal
MTMarwa S. Taha
Marwa S. Taha
To improve clinical decision-making about Carbapenem-resistant Gram-negative bacteria (CR-GNB) infections and halt the spread of resistant microbes, quicker and less expensive diagnostic techniques are required. Thus, the purpose of this study was to thoroughly evaluate the diagnostic efficiency (sensitivity, specificity, and concordance) of direct-from-specimen multiplex lateral flow immunoassay (LFIA) across diverse raw clinical specimens and pathogen types from critically sick patients. A total of 300 non-duplicate samples were tested to detect CR-GNB. Five major Carbapenemase genes were detected directly from the specimen using carbapenem-resistant K.N.I.V.O. detection K-Set and from culture using culture-enhanced multiplex PCR. Turnaround time (TAT) of each method was calculated. The direct LFIA revealed 100% specificity for NDM, KPC, and IMP enzymes in all tested clinical matrices (blood, urine, and respiratory samples). The study demonstrated 100% sensitivity and specificity with perfect categorical agreement (κ = 1.000) for the blaKPC in the Klebsiella pneumoniae and for blaOXA-48 and blaIMP in the Acinetobacter baumannii; however, sensitivity of blaVIM was significantly diminished across all isolates and samples. TAT decreased significantly (p < 0.001) from 30 to 70 h to about 50 min. The tested direct LFIA facilitates the prompt enhancement of lifesaving tailored antibiotic treatment for severe illnesses.